MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Начало・Списък с акции・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

23.53 1.69

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

22.99

Максимум

23.76

Ключови измерители
By Trading Economics
Приходи	-14M -50M
Продажби	12M 128M
Марж на печалбата	-39.506
Служители	1,784
EBITDA	-17M -48M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+48.17% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	200M 2.4B
Предишно отваряне	21.84
Предишно затваряне	23.53

Настроения в новините

By Acuity

42%

58%

135 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

28.13 / 31.12 Подкрепа & съпротива

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.04.2026 г., 23:26 ч. UTC

Горещи акции

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16.04.2026 г., 20:41 ч. UTC

Значими двигатели на пазара

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16.04.2026 г., 23:49 ч. UTC

Пазарно говорене

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16.04.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline After Hitting Record High -- Market Talk

16.04.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16.04.2026 г., 22:51 ч. UTC

Пазарно говорене

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16.04.2026 г., 22:08 ч. UTC

Печалби

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16.04.2026 г., 22:06 ч. UTC

Печалби

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16.04.2026 г., 22:06 ч. UTC

Печалби

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16.04.2026 г., 22:06 ч. UTC

Печалби

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16.04.2026 г., 22:06 ч. UTC

Печалби

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16.04.2026 г., 22:06 ч. UTC

Печалби

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

16.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

16.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

16.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Health Care Roundup: Market Talk

16.04.2026 г., 20:49 ч. UTC

Печалби

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16.04.2026 г., 20:43 ч. UTC

Печалби

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16.04.2026 г., 20:40 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

16.04.2026 г., 20:40 ч. UTC

Пазарно говорене

Печалби

Netflix Says Engagement Quality Hits New High -- Market Talk

16.04.2026 г., 20:30 ч. UTC

Горещи акции

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16.04.2026 г., 20:25 ч. UTC

Печалби

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16.04.2026 г., 20:23 ч. UTC

Печалби

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16.04.2026 г., 20:19 ч. UTC

Печалби

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16.04.2026 г., 20:17 ч. UTC

Печалби

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16.04.2026 г., 20:17 ч. UTC

Печалби

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16.04.2026 г., 20:16 ч. UTC

Печалби

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16.04.2026 г., 20:16 ч. UTC

Печалби

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16.04.2026 г., 20:16 ч. UTC

Печалби

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16.04.2026 г., 20:16 ч. UTC

Печалби

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

48.17% нагоре

12-месечна прогноза

Среден 34.45 USD 48.17%

Висок 47 USD

Нисък 21.8 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Zai Lab Ltd ADR през последните 3 месеца.

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

135 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.